The lobbying arms of two big U.S. law firms have jumped into the cannabis advocacy space with contracts to represent a Delaware pharmaceutical manufacturer.
Alston & Bird and Jones Walker were retained by Noramco Inc. to lobby on federal regulation of cannabidiol, or CBD, according to recent federal disclosures. Although the compound can be derived from both marijuana and hemp, it’s the non-intoxicating hemp-derived CBD that’s at the center of a booming industry producing everything from lip balms to dog treats with the additive. CBD sales are predicted to top $2.3 billion by 2022.
